Drug Profile
GKM 001
Alternative Names: ADV-1002401; GKM-001Latest Information Update: 01 Jan 2023
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 30 Dec 2022 GKM 001 is still in phase I clinical development in Type 2 diabetes mellitus in India (PO) (Impetis Biosciences pipeline, December 2022)
- 17 Jun 2020 GKM 001 is available for licensing as of 17 Jun 2020. https://impetisbiosciences.com/
- 17 Jun 2020 Impetis Biosciences has patent protection for GKM 001 in USA and Europe